ESC Premium Access

Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study

Presentation

About the speaker

Doctor Ole-Christian Walter Rutherford

Sykehuset Ostfold Kalnes, Sarpsborg (Norway)
0 follower

8 more presentations in this session

Equally high detection rates of atrial fibrillation in patients after a TIA and stroke by systematic ECG monitoring with an implanted device: SPIDER-AF study

Speaker: Doctor F. Goss (Munich, DE)

Thumbnail

Non valvular atrial fibrillation, contraindication to anticoagulation or antiplatelet therapy and heart team approach: a single centre experience

Speaker: Doctor A. Graffigna (Trento, IT)

Thumbnail

Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Thumbnail

High mortality in atrial fibrillation patients suffering ischemic stroke, intracranial hemorrhage or a gastrointestinal bleed and associations with the preceding antithrombotic treatment

Speaker: Professor P. Hjemdahl (Stockholm, SE)

Thumbnail

Efficacy and safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation and cancer

Speaker: Doctor I. Cavallari (Rome, IT)

Thumbnail

Access the full session

Prevention of thromboembolism and atrial remodelling in atrial fibrillation

Speakers: Doctor O. Rutherford, Doctor F. Goss, Doctor A. Graffigna, Doctor A. Nissen Bonde, Professor P. Hjemdahl...
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

Related content

ESC Premium Access

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

28 August 2021

This platform is supported by

logo Novo Nordisk